PL2868315T3 - Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty - Google Patents

Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty

Info

Publication number
PL2868315T3
PL2868315T3 PL14188334T PL14188334T PL2868315T3 PL 2868315 T3 PL2868315 T3 PL 2868315T3 PL 14188334 T PL14188334 T PL 14188334T PL 14188334 T PL14188334 T PL 14188334T PL 2868315 T3 PL2868315 T3 PL 2868315T3
Authority
PL
Poland
Prior art keywords
lyophilates
lyophilization
methods
improved formulations
formulations
Prior art date
Application number
PL14188334T
Other languages
English (en)
Inventor
Martin Sven Jacobson
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of PL2868315T3 publication Critical patent/PL2868315T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14188334T 2007-12-04 2008-12-03 Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty PL2868315T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99224107P 2007-12-04 2007-12-04
EP14188334.8A EP2868315B1 (en) 2007-12-04 2008-12-03 Improved formulations and methods for lyophilization and lyophilates provided thereby
EP08857974.3A EP2224913B1 (en) 2007-12-04 2008-12-03 Improved formulations and methods for lyophilization and lyophilates provided thereby

Publications (1)

Publication Number Publication Date
PL2868315T3 true PL2868315T3 (pl) 2018-06-29

Family

ID=40718143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14188334T PL2868315T3 (pl) 2007-12-04 2008-12-03 Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty

Country Status (14)

Country Link
US (6) US8277845B2 (pl)
EP (2) EP2224913B1 (pl)
JP (5) JP5812318B2 (pl)
CN (1) CN101932308B (pl)
CA (3) CA3123813A1 (pl)
CY (1) CY1119256T1 (pl)
DK (1) DK2868315T3 (pl)
ES (1) ES2638977T3 (pl)
HR (1) HRP20171223T1 (pl)
LT (1) LT2868315T (pl)
PL (1) PL2868315T3 (pl)
PT (1) PT2868315T (pl)
SI (1) SI2868315T1 (pl)
WO (1) WO2009073711A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073711A1 (en) * 2007-12-04 2009-06-11 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
US20140287998A1 (en) * 2011-12-09 2014-09-25 Enject, Inc. Glucagon formulations
MX363473B (es) 2012-05-08 2019-03-25 Aeromics Inc Uso de fenilbenzamidas para tratar condiciones mediadas por acuaporina.
GEP20217251B (en) * 2012-05-25 2021-04-26 Charpentier Emmanuelle De Emanuel Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US20160279155A1 (en) 2013-11-06 2016-09-29 Aeromics, Inc. Novel formulations
CN113648464B (zh) * 2014-03-07 2022-12-30 恩朵罗杰克斯有限责任公司 形成水凝胶和用于形成水凝胶的材料
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
MA45307A (fr) 2015-05-29 2018-04-11 Biogen Chesapeake Llc Procédés de réduction ou de prévention des dommages à l'intima provoqués par une stimulation mécanique de cellules endothéliales
EA201890893A1 (ru) 2015-10-07 2018-09-28 БАЙОДЖЕН ЧЕСАПИК ЭлЭлСи Способы лечения повреждений или состояний, относящихся к отеку цнс
US20170320862A1 (en) * 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
WO2018023035A1 (en) 2016-07-29 2018-02-01 Biogen Chesapeake Llc Methods of medical treatment with sur1-trpm4 channel inhibitors
CN108210501B (zh) * 2016-12-14 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种磺酰脲类药物的注射用药物组合物及其制备方法
EP3647229B1 (en) 2017-06-30 2022-09-07 Murata Machinery, Ltd. Conveying system and conveying method
CN108553428A (zh) * 2018-05-29 2018-09-21 昆药集团股份有限公司 格列本脲制剂及其制备方法
WO2022195112A1 (en) 2021-03-19 2022-09-22 Eligo Bioscience Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins for treating acneiform rash
CN113274361B (zh) * 2021-06-08 2022-05-06 吉林津升制药有限公司 一种烟酰胺冻干粉针剂及其制备方法
WO2023168379A1 (en) * 2022-03-03 2023-09-07 Biogen Chesapeake Llc Low-sorbing glyburide kit, formulation and methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
GB9003185D0 (en) * 1990-02-13 1990-04-11 Ici Plc Pharmaceutical compositions
ATE146359T1 (de) 1992-01-21 1997-01-15 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
CA2188682A1 (en) * 1994-04-25 1995-11-02 Tokuyuki Kuroda Method for stabilizing compound dx-52-1 and lyophilized composition thereof
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
SK284989B6 (sk) * 1996-12-24 2006-04-06 Biogen, Inc. Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
SI0999826T1 (en) 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
EP1082132A1 (en) * 1998-05-29 2001-03-14 Biogen, Inc. Recombinant human interferon beta-1a (ifn-beta-1a) formulation
US6552082B2 (en) 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
JP3956654B2 (ja) 2000-06-29 2007-08-08 小野薬品工業株式会社 Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤
US20030175349A1 (en) 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
AU2002306461A1 (en) 2001-03-28 2002-10-15 Rheologics, Inc. In vivo delivery methods and compositions
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP2005501817A (ja) 2001-06-12 2005-01-20 アクティブ パス ファーマシューティカルズ， インコーポレイテッド β−アミロイド産生を調節する化合物、組成物および方法
ATE386523T1 (de) * 2001-07-17 2008-03-15 N Gene Res Lab Inc Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
PT2438913T (pt) 2002-03-20 2020-05-27 Us Veterans Affairs Canal de catiões não seletivos em células neurais e compostos que bloqueiam o canal para utilização no tratamento de edema cerebral
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
DE10341414A1 (de) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
WO2005112949A1 (en) 2004-05-20 2005-12-01 Diamedica Inc. Use of drug combinations for treating insulin resistance
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
AU2006215703A1 (en) 2005-02-17 2006-08-24 Instituto Del Metabolismo Celular, S.L. L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism
US7659281B2 (en) 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
PL2071917T3 (pl) 2006-09-29 2013-04-30 Infa Sa System opakowaniowy dla kompozycji farmaceutycznych oraz zestaw do podawania dożylnego
WO2009073711A1 (en) * 2007-12-04 2009-06-11 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby

Also Published As

Publication number Publication date
JP6084639B2 (ja) 2017-02-22
CN101932308A (zh) 2010-12-29
US10117834B2 (en) 2018-11-06
US20200093747A1 (en) 2020-03-26
ES2638977T3 (es) 2017-10-24
JP2017128569A (ja) 2017-07-27
CA3123813A1 (en) 2009-06-11
EP2868315A1 (en) 2015-05-06
JP5812318B2 (ja) 2015-11-11
US8277845B2 (en) 2012-10-02
US10426729B2 (en) 2019-10-01
HRP20171223T1 (hr) 2017-11-03
JP2018197244A (ja) 2018-12-13
PT2868315T (pt) 2017-09-04
US20130245069A1 (en) 2013-09-19
CA3240562A1 (en) 2009-06-11
JP2020007334A (ja) 2020-01-16
US20150141516A1 (en) 2015-05-21
WO2009073711A1 (en) 2009-06-11
CN101932308B (zh) 2014-11-05
US20210244669A1 (en) 2021-08-12
JP6866438B2 (ja) 2021-04-28
CY1119256T1 (el) 2018-02-14
EP2224913A1 (en) 2010-09-08
US20100273886A1 (en) 2010-10-28
DK2868315T3 (en) 2017-09-04
JP6603762B2 (ja) 2019-11-06
US20190099372A1 (en) 2019-04-04
US8858997B2 (en) 2014-10-14
EP2224913B1 (en) 2014-10-15
JP6377189B2 (ja) 2018-08-22
EP2868315B1 (en) 2017-05-31
JP2015134763A (ja) 2015-07-27
EP2224913A4 (en) 2013-04-24
JP2011505424A (ja) 2011-02-24
CA2707484A1 (en) 2009-06-11
LT2868315T (lt) 2017-09-25
US10869835B2 (en) 2020-12-22
CA2707484C (en) 2021-08-10
SI2868315T1 (sl) 2017-10-30

Similar Documents

Publication Publication Date Title
HRP20171223T1 (hr) Poboljšane formulacije i postupci liofiliziranja i tako dobiveni liofilizati
HK1218427A1 (zh) 改進的疫苗及其使用方法
EP2043647A4 (en) FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS
ZA201203709B (en) Immunogenic compositions and methods
HK1138188A1 (en) Solid preparation comprising alogliptin and pioglitazone
SG10201501296SA (en) Lyophilized therapeutic peptibody formulations
IL197781A0 (en) Lyophilization methods and apparatuses
PT2205336T (pt) Sistema e método para produzir formulações secas
EP2461691A4 (en) THERAPEUTIC VITAMIN D SUNSCREEN FORMULATIONS AND METHOD OF USE THEREOF
HK1244426A1 (zh) 治療性蛋白質製劑
EP2367444A4 (en) MEDICAL AND NUTRITIONAL FORMULATIONS
EP2209750A4 (en) CEMENT FORMULATIONS AND PRODUCTS
EP2185112A4 (en) STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS
EP2160183A4 (en) QUETIPIN EXTENDED FORMULATIONS WITH EXTENDED RELEASE AND METHOD OF MANUFACTURING THEREOF
PL2207567T3 (pl) Preparat immunogenny
SI2320739T1 (sl) Farmacevtski sestavki in postopki za njihovo stabiliziranje
ZA200903049B (en) Polymer-linked-bisphosphonate inhalant formulations and methods for using the same
EP2219606A4 (en) INJECTABLE FORMULATIONS OF MÉCLIZINE AND METHODS RELATED THERETO
ZA201008384B (en) Lasalocid compositions and methods
EP2348865A4 (en) BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE
GB0711465D0 (en) Silan-3-amines and disilan-5-amines as therapeutic agents
GB0725007D0 (en) Carcino-immune therapeutic animal gland extract
GB0713093D0 (en) Pharmaceutical formulations
GB0715066D0 (en) Tobacco extraction methods and formulations